Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1Phase 3 1

Status

Recruiting 2Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 1

Conditions

Prolactinoma 2Hyperprolactinemia 2Prolactin Deficiency, Isolated 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Cabergoline × 1 year × Clear all
NCT07463235 2026-03-13

SPARAGMOS

University of Sao Paulo General Hospital

Phase 3 Recruiting
70 enrolled

Hyperprolactinemia, Prolactinoma

NCT07045935 2025-09-23

ProBOLIC

University Hospital, Basel, Switzerland

Phase 4 Recruiting
60 enrolled

Prolactin Deficiency, Isolated, Hyperprolactinemia, Prolactinoma

NCT07168837 2025-09-11

Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction

Al-Azhar University

Phase NA Completed
100 enrolled

Polycystic Ovary Syndrome

NCT07034859 2025-06-24

Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

National Taiwan University Hospital

Phase 4 Enrolling by invitation
30 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡